Metoject Pen

Methotrexate, the active ingredient in Metoject Pen, is an antimetabolite presented as a pre‑filled pen for subcutaneous injection. It is used to manage autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as certain cancers including acute lymphoblastic leukemia and non‑Hodgkin lymphoma.

GNH USA supplies Metoject Pen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides cold‑chain logistics to maintain product integrity during global shipment.

Methotrexate is an antimetabolite used in autoimmune and oncologic conditions.

Rheumatoid arthritis: reduces joint inflammation and slows disease progression. Psoriasis: limits skin cell proliferation and improves plaque appearance. Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. Non‑Hodgkin lymphoma: impedes tumor growth by disrupting DNA synthesis.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or general weakness. - Mouth sores or oral ulceration. - Elevated liver enzymes. - Mild rash or itching. - Transient low blood cell counts.

Serious or Rare Side Effects: - Pulmonary toxicity, including interstitial pneumonitis. - Severe liver injury or fibrosis. - Bone marrow suppression leading to pancytopenia. - Life‑threatening infections due to immunosuppression. - Renal failure or nephrotoxicity. - Anaphylactic or severe allergic reactions.

Before using Metoject Pen, several safety considerations are essential.

Pregnancy: contraindicated (Category X) due to high teratogenic risk. Renal function: assess baseline; adjust or avoid if severe impairment. Liver function: monitor enzymes regularly; avoid in advanced hepatic disease. Hematologic monitoring: perform complete blood counts frequently to detect cytopenias. Infection risk: screen for latent infections and avoid use during active infections. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its safety or effectiveness.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase toxicity. - Penicillins: reduce renal clearance, raising methotrexate levels. - Proton pump inhibitors: may elevate systemic exposure. - Live vaccines: heightened risk of infection.

Moderate Interactions (Monitor Closely): - Sulfonamides: additive bone‑marrow suppression. - Trimethoprim‑sulfamethoxazole: similar hematologic risk. - Azathioprine: combined immunosuppression may increase infection risk. - Alcohol: can exacerbate liver toxicity.